Biovail hammered by patent ruling
Article Abstract:
Biovail Corp. has lost a patent infringement case, allowing production of a cheaper version of its drug Wellbutrin XL, leading to decrease in its share values.
Publisher: Bell Globemedia Interactive
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2006
Pharmaceutical preparations, Securities issued, listed, Patents & copyrights, Securities, Intellectual property, Company securities, Biovail Corp., Patent infringement, Wellbutrin XL (Medication)
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Apotex wins legal fight over drug
Article Abstract:
Apotex Inc. wins a legal battle in its efforts to manufacture a copy version of GlaxoSmithKline PLC's anti-depressant drug Paxil.
Publisher: Bell Globemedia Interactive
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2003
United Kingdom, Paxil (Medication), GlaxoSmithKline PLC, Apotex Inc.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: Canada, Company legal issue, Cases, Pharmaceutical industry
Similar abstracts:
- Abstracts: Britain debates complex issues of joined twins. TLC threatens legal action over Web addresses. Implants to treat prostate cancer will be common:doctor
- Abstracts: Zemex threatens to cancel takeover if Inmet pays debt. Placer says Marcopper Mining responsible for river cleanup
- Abstracts: On-line travel agent signs deal with German firm. Bombardier talks with rail firms; denies deal for Adtranz. DaimlerChrysler investment not likely to create jobs
- Abstracts: RT condoned illegal trades: OSC. Royal unit suspends 4 workers
- Abstracts: Vivendi finalizes deal for USA Networks assets. Bronfmans win in Seagram deal
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.